Maravai Lifesciences Holdings (MRVI) AI Stock Analysis
Maravai Lifesciences Holdings
(BMV:MRVI)
No summary available
Maravai Lifesciences Holdings (MRVI) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- MXN 2.22B
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -14.6
- Beta (1Y)
- 0.13
- Revenue Growth
- -12.00%
- EPS Growth
- 63.49%
- Country
- Mexico
- Employees
- 415
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Maravai Lifesciences Holdings Business Overview & Revenue Model
Company Description
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product...
Maravai Lifesciences Holdings Earnings Call Summary
The earnings call conveyed strong operational progress and financial improvement: revenue growth, large margin expansion, significantly improved adjusted EBITDA, record customer additions, product launches and patent wins, plus a materially strengthened balance sheet via refinancing. The primary negatives are that GAAP losses persist, certain businesses (CDMO and some new products) remain lumpy or early-stage, and timing risk exists around large program-driven orders and GMP conversions. On balance, the call emphasized accelerating commercial execution and durable margin improvement, with management maintaining prudent revenue guidance while raising confidence in profitability.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management reiterated 2026 revenue guidance of $205–$215 million (growth of ~10%–16% vs. 2025) while raising full‑year adjusted EBITDA to $33–$35 million (an implied year‑over‑year improvement of roughly $64–$66 million), and now expects gross margin expansion of greater than 1,400 basis points; they expect TriLink growth in the high‑teens and Cygnus growth in the low‑ to mid‑single digits, noted mRNA (excluding COVID) is ~35% of expected 2026 revenue, CDMO <5% and specialty chemistry a bit over 20%, reminded investors COVID CleanCap was $14.3 million in Q1 (about 7% of midpoint guidance), said GMP ModTail orders are not assumed in 2H (expected revenue impact in 2027), highlighted first enzyme GMP order shipped, and cited a stronger balance sheet with $70.1 million cash and ~$147.1–$150 million debt after refinancing with maturities extended to 2032 as reasons for their prudent but more confident profitability outlook.
Maravai Lifesciences Holdings Risk Analysis
Maravai Lifesciences Holdings disclosed 74 risk factors in its most recent earnings report. Maravai Lifesciences Holdings reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksMaravai Lifesciences Holdings Peers Comparison
Overall Rating
OABI69Neutral
FTRE60Neutral
ABSI59Neutral
DNA46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| OABI | 69Neutral | $742.94M | -15.03 | -16.73% | ― | 90.63% | 42.74% |
| FTRE | 60Neutral | $2.05B | -28.25 | -12.81% | ― | -3.38% | 93.48% |
| ABSI | 59Neutral | $1.91B | -13.91 | -59.21% | ― | -62.28% | 15.36% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| DNA | 46Neutral | $754.88M | -2.23 | -60.21% | ― | -51.54% | 7.05% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MX:MRVI | Maravai Lifesciences Holdings, Inc. | 135.00 | 50.00 | 58.82% | |
| DNA | Ginkgo Bioworks Holdings, Inc. | 11.21 | -1.58 | -12.35% | |
| ABSI | Absci Corp. | 11.13 | 7.02 | 170.80% | |
| OABI | Omniab, Inc. | 5.11 | 3.63 | 245.27% | |
| FTRE | Fortrea Holdings Inc. | 21.29 | 11.17 | 110.38% | |
| ALMR | Alamar Biosciences, Inc. | 30.60 | 8.60 | 39.09% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.